Expansion and persistence of cell products have been linked to efficacy and safety outcomes. Monitoring of cell product kinetics is important in cell therapy product development.
AlloCell is a universal solution, applicable across both engineered and non-engineered allogeneic cell therapies.
Based on a comprehensive panel of genomic signatures, AlloCell accurately measures the proportion of cell product cells, while preserving the confidentiality of genome engineering constructs.
CareDx leverages years of experience with high-throughput NGS sample processing to offer AlloCell as a comprehensive end-to-end solution, that does not require our Partners to set up any laboratory workflows.
Our streamlined standardized laboratory workflow ensures timely, high quality processing.
Dedicated Project Manager and attentive AlloCell Team enable seamless integration with our Partners’ processes.
AlloCell is a ready-to-use solution for monitoring of allogeneic CAR-T cells — no need for assay development, no delays — we can onboard your cell product within days and deliver meaningful results.
AlloCell is also directly applicable for CAR-NK and non-engineered allogeneic cell therapies.
1. Neelapu et al, 2020. First-in-human data of ALLO-501 and ALLO-647 in relapsed/refractory large B-cell or follicular lymphoma (R/R LBCL/FL): ALPHA study. Presented at the ASCO 2020 Annual Meeting by Sattva Neelapu, M.D.
2. CareDx data on file.
3. Aftab et al, 2021. A Sensitive and Precise Universal Surveillance Solution for Pharmacokinetic Monitoring of Off-the-Shelf Cell Therapies. Poster 204. Transplantation & Cellular Therapy Meetings™ of ASTCT® and CIBMTR® 2021.
